D81098Z
Brachytherapy Eye to None with Iridium 192 (Ir-192), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 8 Eye |
| Operation | 1 Brachytherapy |
| Body Part | 0 Eye |
| Approach | 9 High Dose Rate (HDR) |
| Device | 8 Iridium 192 (Ir-192) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy to the eye involves placing a radioactive source, most commonly a small plaque containing radioactive seeds, directly on or very near the eye to treat a tumor such as choroidal or ciliary body melanoma. Because the source sits right against the affected tissue, radiation is delivered at close range while sparing much of the surrounding eye from the higher doses an external beam would require to reach the same depth.
This technique is often selected specifically because it allows the eye to be preserved when a tumor is suitably sized and positioned, offering a real alternative to removal of the eye in appropriately selected cases. The plaque is typically sutured in place during a short surgical procedure and then removed after a set number of days once the prescribed dose has been delivered.
Care teams weigh plaque brachytherapy against external beam or surgical options based on tumor size, location, and how much of the eye's function might reasonably be preserved.
Anatomy & Axis Detail
Eye
Brachytherapy applied to the eye typically involves placing a radioactive plaque, most often affixed to the outer surface of the sclera, directly over an intraocular tumor such as a choroidal or ciliary body melanoma. This approach allows a high dose to be delivered to the tumor while sparing much of the surrounding retina, optic nerve, and lens compared to external methods, which is particularly valuable given how easily nearby ocular structures are injured by radiation. Plaque placement requires surgical exposure of the globe and careful localization against the tumor base, and the plaque is later removed after the prescribed treatment period. Because the source is temporarily implanted rather than beamed from outside, this is documented separately from beam or stereotactic radiation to the same eye.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Iridium 192 (Ir-192)
Iridium-192 is a gamma-emitting radioisotope used almost exclusively for high-dose-rate or pulsed-dose-rate brachytherapy, delivered via remote afterloader through catheters or applicators placed in or near the tumor. It allows a shaped, temporary dose to sites like the cervix, prostate, or breast cavity, then the source is withdrawn rather than left implanted, distinguishing it from permanent seed isotopes such as I-125 or Pd-103.
Coding & Documentation
Supporting documentation should describe placement of a radioactive plaque or source against or within the eye, along with the operative note for insertion and, later, removal of the device. Coders need both procedures represented if the plaque is placed in one encounter and retrieved in another.
A frequent error is coding only the insertion and overlooking the later removal encounter, or conversely coding the removal as if it were a new radiation delivery procedure. Coders should also verify the specific eye structure treated is reflected accurately rather than defaulting to a general eye code when the operative note specifies choroid, ciliary body, or another distinct site.